Calcium channel blocker use and risk of Parkinson's disease

Kelly Claire Simon; Xiang Gao; Honglei Chen; Michael A. Schwarzschild; Alberto Ascherio

doi:10.1002/mds.23191

Calcium channel blocker use and risk of Parkinson's disease

Kelly Claire Simon, Xiang Gao, Honglei Chen, Michael A. Schwarzschild, Alberto Ascherio

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

Original language	English (US)
Pages (from-to)	1818-1822
Number of pages	5
Journal	Movement Disorders
Volume	25
Issue number	12
DOIs	https://doi.org/10.1002/mds.23191
State	Published - Sep 15 2010

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.1002/mds.23191

Cite this

@article{b7a73f4cc7b04ed7a952b4794315755b,

title = "Calcium channel blocker use and risk of Parkinson's disease",

abstract = "We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.",

author = "Simon, {Kelly Claire} and Xiang Gao and Honglei Chen and Schwarzschild, {Michael A.} and Alberto Ascherio",

year = "2010",

month = sep,

day = "15",

doi = "10.1002/mds.23191",

language = "English (US)",

volume = "25",

pages = "1818--1822",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley & Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Calcium channel blocker use and risk of Parkinson's disease

AU - Simon, Kelly Claire

AU - Gao, Xiang

AU - Chen, Honglei

AU - Schwarzschild, Michael A.

AU - Ascherio, Alberto

PY - 2010/9/15

Y1 - 2010/9/15

N2 - We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

AB - We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

UR - http://www.scopus.com/inward/record.url?scp=77956860900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956860900&partnerID=8YFLogxK

U2 - 10.1002/mds.23191

DO - 10.1002/mds.23191

M3 - Article

C2 - 20669249

AN - SCOPUS:77956860900

SN - 0885-3185

VL - 25

SP - 1818

EP - 1822

JO - Movement Disorders

JF - Movement Disorders

IS - 12

ER -

Calcium channel blocker use and risk of Parkinson's disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this